CoChat
Sign Up
Cited by 180HIV/AIDS Research and InterventionsHIV, Drug Use, Sexual RiskHIV/AIDS drug development and treatment

Acceptability of pre-exposure prophylaxis as an HIV prevention strategy: barriers and facilitators to pre-exposure prophylaxis uptake among at-risk Peruvian populations

Open access
Galea, J T, Kinsler, J J, Salazar, X, Lee, S-J, Giron, M, Sayles, J N, Cáceres, C, Cunningham, W E·2011·International Journal of STD & AIDS
DOI 10.1258/ijsa.2009.009255PMC PMC3096991
Open this paper in CoChat — free account

Abstract

This study examined pre-exposure prophylaxis (PrEP) acceptability among female sex workers, male-to-female transgendered persons and men who have sex with men in Lima, Peru. Focus groups explored social issues associated with PrEP acceptability and conjoint analysis assessed preferences among eight hypothetical PrEP scenarios with varying attribute profiles and their relative impact on acceptability. Conjoint analysis revealed that PrEP acceptability ranged from 19.8 to 82.5 out of a possible score of 100 across the eight hypothetical PrEP scenarios. Out-of-pocket cost had the greatest impact on PrEP acceptability (25.2, P < 0.001), followed by efficacy (21.4, P < 0.001) and potential side-effects (14.7, P < 0.001). Focus group data supported these findings, and also revealed that potential sexual risk disinhibition, stigma and discrimination associated with PrEP use, and mistrust of healthcare professionals were also concerns. These issues will require careful attention when planning for PrEP roll-out.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1258/ijsa.2009.009255

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 32

  1. [1]Steinbrook R One step forward, two steps back--will there ever be an AIDS vaccine? N Engl J Med 2007 357 2653 2655 18160684
  2. [2]Vissers DC Voeten HA Nagelkerke NJ Habbema J De Vlas S The impact of pre-exposure prophylaxis (PrEP) on HIV epidemics in Africa and India: a simulation study PLoS ONE 2008 3 e2077 18461185 PMC2367053
  3. [3]Skoler-Karpoff S Ramjee G Ahmed K Efficacy of Carraguard for prevention of HIV infection in women in South Africa: A randomised, double-blind, placebo-controlled trial Lancet 2008 372 1977 1987 19059048
  4. [4]Youle M Wainberg MA Pre-exposure chemoprophylaxis (PREP) as an HIV prevention strategy J Int Assoc Physicians AIDS Care (Chic Ill) 2003 2 102 105 14556428
  5. [5]Smith SM Pre-exposure chemoprophylaxis for HIV: It is time Retrovirology 2004 1 16 15238164 PMC478616
  6. [6]Stephenson J New HIV prevention strategies urged: Averting new infections key to controlling pandemic JAMA 2004 292 1163 1164 15353518
  7. [7]Cohen MS Gay C Kashuba AD Blower S Paxton L Narrative review: Antiretroviral therapy to prevent the sexual transmission of HIV-1 Ann Intern Med 2007 146 591 601 17438318
  8. [8]Liu AY Kittredge PV Vittinghoff E Limited knowledge and use of HIV post- and pre-exposure prophylaxis among gay and bisexual men J Acquir Immune Defic Syndr 2008 47 241 247 18340656
  9. [9]Guay LA Musoke P Fleming T Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial Lancet 1999 354 795 802 10485720
  10. [10]Lallemant M Jourdain G Le Coeur S Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand N Engl J Med 2004 351 217 228 15247338
  11. [12]Goicohea P Lama JR Leon R Grant RM Reducing participant’s information gap in HIV prevention clinical research AIDS 2008 XVII International AIDS Conference, 2008
  12. [13]Lama JR Guanira J Goicochea P Willingness to participate in a HIV pre-exposure prophylaxis efficacy trial among high risk men who have sex with men in the Andean region 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention 2007
  13. [14]Nodin N Carballo-Dieguez A Ventuneac AM Balan I Remien R Knowledge and acceptability of alternative HIV prevention bio-medical products among MSM who bareback AIDS Care 2008 20 106 115 18278621
  14. [15]Kellerman SE Hutchinson AB Begley EB Boyett BC Clark HA Sullivan P Knowledge and use of HIV pre-exposure prophylaxis among attendees of minority gay pride events, 2004 J Acquir Immune Defic Syndr 2006 43 376 377 17079995
  15. [17]Montano SM Sanchez JL Laguna-Torres A Prevalences, genotypes, and risk factors for HIV transmission in South America J Acquir Immune Defic Syndr 2005 40 57 64 16123683
  16. [18]Miller GA Mendoza W Krone MR Clients of female sex workers in Lima, Peru: A bridge population for sexually transmitted disease/HIV transmission? Sex Transm Dis 2004 31 337 342 15167641
  17. [19]Sayles JN Macphail C Newman P Cunningham WE Future HIV Vaccine Acceptability Among Young Adults in South Africa Journal of Health Education and Behavior June 2009 epub PMC2866130 19509123
  18. [26]Phillips KA Maddala T Johnson FR Measuring preferences for health care interventions using conjoint analysis: an application to HIV testing Health Serv Res 2002 37 6 1681 1705 12546292 PMC1464051
  19. [27]Ryan M Farrar S Using conjoint analysis to elicit preferences for health care BMJ 2000 320 1530 1533 10834905 PMC1118112
  20. [28]Newman PA Duan N Lee SJ HIV vaccine acceptability among communities at risk: The impact of vaccine characteristics Vaccine 2006 24 2094 2101 16332402 PMC2819665
  21. [29]Lee SJ Brooks RA Newman PA Seiden D Songthong R Duan N HIV vaccine acceptability among immigrant Thai residents in Los Angeles: A mixed-method approach AIDS Care 2008 20 1161 1168 18608068 PMC2828810
  22. [30]Newman PA Duan N Lee SJ Willingness to participate in HIV vaccine trials: The impact of trial attributes Prev Med 2007 44 554 557 17275895 PMC2819663
  23. [31]Duan N Listening to consumers and HIV vaccine PrEParedness Lancet 2005 365 1119 1121 15794955
  24. [32]Ryan M McIntosh E Shackley P Methodological issues in the application of conjoint analysis in health care Health Economics 1988 7 373 378 9683097
  25. [33]Valencia-Garcia D Starks H Strick L After the fall from grace: negotiation of new identities among HIV-positive women in Peru Cult Health Sex 2008 10 739 752 18821355 PMC2704982
  26. [34]Clark JL Long CM Giron JM Partner notification for sexually transmitted diseases in Peru: Knowledge, attitudes, and practices in a high risk community sex Transm Dis 2007 34 309 313 17016236
  27. [35]Abbas UL Anderson RM Mellors JW Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings PLoS ONE 2007 2 9 e875 17878928 PMC1975470
  28. [36]Guest G Johnson L Burke H Changes in sexual behavior during a safety and feasibility trial of a microbicide/diaphragm combination: An integrated qualitative and quantitative analysis AIDS Educ Prev 2007 19 310 320 17685844
  29. [37]Cassell M Halperin D Shelton J Risk compensation: The achilles’ heel of innovations in HIV prevention BMJ 2006 332 605 607 16528088 PMC1397752
  30. [38]Pinkerton S Sexual risk compensation and HIV/STD transmission: empirical evidence and theoretical considerations Risk Anal 2001 21 727 736 11726023
  31. [39]Newman PA Duan N Rudy ET Roberts KJ Swendeman D Posttrial HIV vaccine adoption: Concerns, motivators, and intentions among persons at risk for HIV J Acquir Immune Defic Syndr 2004 37 1393 1403 15483469
  32. [40]Liau A Zimet GD The acceptability of HIV immunization: Examining vaccine characteristics as determining factors AIDS Care 2001 13 643 650 11571011

Cited by

Sorted by citations

Authors
Galea, J. T., Kinsler, J. J., Salazar, X., Lee, S.-J., Giron, M., Sayles, J. N., Cáceres, C., & Cunningham, W. E.
Affiliations
  • University of California, Los Angeles (US)
  • Universidad Peruana Cayetano Heredia (PE)
Corresponding author
Galea, J T
ORCID
Venue
International Journal of STD & AIDS
Publisher
SAGE Publications
Published
2011-05
Volume
22
Issue
5
Pages
256-262
ISSN
  • 0956-4624 (ISSN-L)
  • 1758-1052
DOI
10.1258/ijsa.2009.009255
PMC
PMC3096991
OpenAlex
W2128124766
Cited by
180
References
1
Citations by year
2026: 6 · 2025: 3 · 2024: 9 · 2023: 7 · 2022: 14 · 2021: 21 · 2020: 10 · 2019: 14 · 2018: 11 · 2017: 14 · 2016: 20 · 2015: 8 · 2014: 18 · 2013: 12 · 2012: 9
FWCI
9.28
Type
journal article
Language
en
Open access
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • International Journal of STD & AIDS (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • Digital Commons - University of South Florida (University of South Florida) (submittedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • National Institutes of Health (P30-AG02-1684)
  • National Institute on Aging (P30AG021684)
  • National Institute of Mental Health (K01MH085503)
  • National Center on Minority Health and Health Disparities
Topics
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
  • Health Sciences › Medicine › Epidemiology › HIV, Drug Use, Sexual Risk
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
Keywords
pre-exposure prophylaxis, PrEP acceptability, HIV prevention, female sex workers, transgender women, men who have sex with men, out-of-pocket costs, PrEP efficacy, adverse effects, stigma and discrimination, PrEP uptake barriers, PrEP preferences, Lima
MeSH terms
Adult, Female, Humans, Male, Patient Acceptance of Health Care, Peru, Sex Work, Transvestism, HIV Infections, Focus Groups, Homosexuality, Male, Chemoprevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review